SPRY stock icon

ARS Pharmaceuticals
SPRY

$11.33
0.35%

Market Cap: 1.1B

 

About: ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Employees: 24

0
Funds holding %
of 6,702 funds
Analysts bullish %
0
News positive %
of 25 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

528% more call options, than puts

Call options by funds: $6.42M | Put options by funds: $1.02M

93% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 14

67% more capital invested

Capital invested by funds: $367M [Q4 2023] → $612M (+$245M) [Q1 2024]

50% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2023] → 3 (+1) [Q1 2024]

33% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 27

13% more funds holding

Funds holding: 100 [Q4 2023] → 113 (+13) [Q1 2024]

7.75% less ownership

Funds ownership: 69.82% [Q4 2023] → 62.06% (-7.75%) [Q1 2024]

Research analyst outlook

2 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$18
59%
upside
Avg. target
$18.50
63%
upside
High target
$19
68%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
Wedbush
Andreas Argyrides
68%upside
$19
Outperform
Reiterated
11 Mar 2024
Leerink Partners
Roanna Ruiz
59%upside
$18
Outperform
Upgraded
5 Mar 2024

Financial journalist opinion

Based on 25 articles about SPRY published over the past 30 days